AstraZeneca Rare Disease Drug Misses Phase 3 Target Hope Shifts to Subgroup Data

AstraZeneca announced that its rare disease therapy, anselamimab, failed to achieve the primary endpoint in the pivotal Phase 3 CARES trial for AL amyloidosis. The study, which evaluated patients with advanced Mayo stage IIIa and IIIb cardiac amyloidosis, did not show a statistically significant benefit in survival or reduction of cardiovascular hospitalizations compared to placebo.

Despite the setback, AstraZeneca highlighted encouraging trends in a pre-defined subgroup, suggesting that anselamimab’s targeted amyloid clearance could address critical organ damage in select patients. The company is now analyzing the full dataset to better understand safety and efficacy, and will present detailed findings at an upcoming medical conference.

Developed by AstraZeneca’s rare disease division, Alexion, anselamimab is a novel monoclonal antibody designed to remove harmful amyloid deposits, with the aim of improving organ function. The therapy has received Fast Track status from the US FDA and Orphan Drug Designation from the European Commission.

AL amyloidosis remains a life-threatening condition with limited treatment options, as amyloid buildup in the heart and kidneys often leads to organ failure and early mortality. AstraZeneca’s results underline the ongoing challenges in developing therapies for this rare disorder.